Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression-Reference-Cited by-同舟云学术

Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression

Published:2021-02 Issue:4 Volume:106 Page:520-528
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Bartels Stephan¹^ORCID,Vogtmann Julia¹,Schipper Elisa¹,Büsche Guntram¹,Schlue Jerome¹,Lehmann Ulrich¹,Kreipe Hans¹

Affiliation:

1. Institut für Pathologie Medizinische Hochschule Hannover Hannover Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13579

Reference35 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

3. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

4. Comparison ofJAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

5. Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics and genomics in CML and other myeloproliferative neoplasms;Best Practice & Research Clinical Haematology;2024-06

2. Molecular testing in myeloproliferative neoplasms;Diagnostic Molecular Pathology;2024

3. Research progress of additional pathogenic mutations in chronic neutrophilic leukemia;Annals of Hematology;2023-11-22

4. Genomic alterations in blast phase of BCR::ABL1‐negative myeloproliferative neoplasms;International Journal of Laboratory Hematology;2023-10-22

5. The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis;Frontiers in Oncology;2023-08-11